45 related articles for article (PubMed ID: 26505795)
1. Osteosarcoma cell death induced by innovative scaffolds doped with chemotherapeutics.
Lanzillotti C; Iaquinta MR; De Pace R; Mosaico M; Patergnani S; Giorgi C; Tavoni M; Dapporto M; Sprio S; Tampieri A; Montesi M; Martini F; Mazzoni E
J Cell Physiol; 2024 May; 239(5):e31256. PubMed ID: 38591855
[TBL] [Abstract][Full Text] [Related]
2. Comparative oncology approach to drug repurposing in osteosarcoma.
Parrales A; McDonald P; Ottomeyer M; Roy A; Shoenen FJ; Broward M; Bruns T; Thamm DH; Weir SJ; Neville KA; Iwakuma T; Fulbright JM
PLoS One; 2018; 13(3):e0194224. PubMed ID: 29579058
[TBL] [Abstract][Full Text] [Related]
3. Synergistic Chemoimmunotherapy Augmentation via Sequential Nanocomposite Hydrogel-Mediated Reprogramming of Cancer-Associated Fibroblasts in Osteosarcoma.
Wang H; Chen Y; Wei R; Zhang J; Zhu J; Wang W; Wang Z; Wupur Z; Li Y; Meng H
Adv Mater; 2024 Apr; 36(15):e2309591. PubMed ID: 38113900
[TBL] [Abstract][Full Text] [Related]
4. Roles and therapeutic targeting of ceramide metabolism in cancer.
Wajapeyee N; Beamon TC; Gupta R
Mol Metab; 2024 May; 83():101936. PubMed ID: 38599378
[TBL] [Abstract][Full Text] [Related]
5. Bioactive Lipids and Their Derivatives in Biomedical Applications.
Park J; Choi J; Kim DD; Lee S; Lee B; Lee Y; Kim S; Kwon S; Noh M; Lee MO; Le QV; Oh YK
Biomol Ther (Seoul); 2021 Sep; 29(5):465-482. PubMed ID: 34462378
[TBL] [Abstract][Full Text] [Related]
6. CCR1 Activation Promotes Neuroinflammation Through CCR1/TPR1/ERK1/2 Signaling Pathway After Intracerebral Hemorrhage in Mice.
Yan J; Zuo G; Sherchan P; Huang L; Ocak U; Xu W; Travis ZD; Wang W; Zhang JH; Tang J
Neurotherapeutics; 2020 Jul; 17(3):1170-1183. PubMed ID: 31898284
[TBL] [Abstract][Full Text] [Related]
7. Novel Sphingolipid-Based Cancer Therapeutics in the Personalized Medicine Era.
Shaw J; Costa-Pinheiro P; Patterson L; Drews K; Spiegel S; Kester M
Adv Cancer Res; 2018; 140():327-366. PubMed ID: 30060815
[TBL] [Abstract][Full Text] [Related]
8. Ginseng Rh2 protects endometrial cells from oxygen glucose deprivation/re-oxygenation.
Tang XF; Liu HY; Wu L; Li MH; Li SP; Xu HB
Oncotarget; 2017 Dec; 8(62):105703-105713. PubMed ID: 29285285
[TBL] [Abstract][Full Text] [Related]
9. ERK inhibition sensitizes CZ415-induced anti-osteosarcoma activity
Yin G; Fan J; Zhou W; Ding Q; Zhang J; Wu X; Tang P; Zhou H; Wan B; Yin G
Oncotarget; 2017 Oct; 8(47):82027-82036. PubMed ID: 29137241
[TBL] [Abstract][Full Text] [Related]
10. Ceramide-containing liposomes with doxorubicin: time and cell-dependent effect of C6 and C12 ceramide.
Øverbye A; Holsæter AM; Markus F; Škalko-Basnet N; Iversen TG; Torgersen ML; Sønstevold T; Engebraaten O; Flatmark K; Mælandsmo GM; Skotland T; Sandvig K
Oncotarget; 2017 Sep; 8(44):76921-76934. PubMed ID: 29100358
[TBL] [Abstract][Full Text] [Related]
11. Assessment of GSK1904529A as a promising anti-osteosarcoma agent.
Fei HD; Yuan Q; Mao L; Chen FL; Cui ZH; Tao S; Ji F
Oncotarget; 2017 Jul; 8(30):49646-49654. PubMed ID: 28572530
[TBL] [Abstract][Full Text] [Related]
12. microRNA-135b expression silences Ppm1e to provoke AMPK activation and inhibit osteoblastoma cell proliferation.
Li ZW; Zhu YR; Zhou XZ; Zhuo BB; Wang XD
Oncotarget; 2017 Apr; 8(16):26424-26433. PubMed ID: 28460435
[TBL] [Abstract][Full Text] [Related]
13. Liposomal C6 Ceramide Activates Protein Phosphatase 1 to Inhibit Melanoma Cells.
Jiang F; Jin K; Huang S; Bao Q; Shao Z; Hu X; Ye J
PLoS One; 2016; 11(9):e0159849. PubMed ID: 27631768
[TBL] [Abstract][Full Text] [Related]
14. Liposomal short-chain C6 ceramide induces potent anti-osteosarcoma activity in vitro and in vivo.
Zhai L; Sun N; Han Z; Jin HC; Zhang B
Biochem Biophys Res Commun; 2015 Dec 4-11; 468(1-2):274-80. PubMed ID: 26505795
[TBL] [Abstract][Full Text] [Related]
15. C6 ceramide sensitizes pemetrexed-induced apoptosis and cytotoxicity in osteosarcoma cells.
Zhu X; Du X; Deng X; Yi H; Cui S; Liu W; Shen A; Cui Z
Biochem Biophys Res Commun; 2014 Sep; 452(1):72-8. PubMed ID: 25152399
[TBL] [Abstract][Full Text] [Related]
16. Dual mTORC1/2 inhibition by INK-128 results in antitumor activity in preclinical models of osteosarcoma.
Jiang H; Zeng Z
Biochem Biophys Res Commun; 2015 Dec 4-11; 468(1-2):255-61. PubMed ID: 26514724
[TBL] [Abstract][Full Text] [Related]
17. C6 ceramide sensitizes the anti-hepatocellular carcinoma (HCC) activity by AZD-8055, a novel mTORC1/2 dual inhibitor.
Liu M; Gu P; Guo W; Fan X
Tumour Biol; 2016 Aug; 37(8):11039-48. PubMed ID: 26897748
[TBL] [Abstract][Full Text] [Related]
18. Present Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma.
Shaikh AB; Li F; Li M; He B; He X; Chen G; Guo B; Li D; Jiang F; Dang L; Zheng S; Liang C; Liu J; Lu C; Liu B; Lu J; Wang L; Lu A; Zhang G
Int J Mol Sci; 2016 Apr; 17(4):506. PubMed ID: 27058531
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
